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The incorporation of transition metal catalysts to the bioorthogonal toolbox has opened the possibility of
producing supra-stoichiometric amounts of xenobiotics in living systems in a non-enzymatic fashion. For
medical use, such metals could be embedded in implantable devices (i.e. heterogeneous catalyst) to
“synthesize” drugs in desired locations (e.g. in a tumour) with high speciﬁcity and for extended periods of
time, overcoming the useful life limitations of current local therapy modalities directed to speciﬁc organ
sites (e.g. brachytherapy, controlled release systems). To translate this approach into a bona ﬁde
therapeutic option, it is essential to develop clinically-accessible implantation procedures and to
understand and validate the activation process in relevant preclinical models. Herein we report the
development of a novel Pd-activatable precursor of the red-ﬂuorescent drug doxorubicin and Pd
devices of optimized size and activity. Screening in state-of-the-art cancer models provided
fundamental insights into the insertion protocols, safety and stability of the devices and into the prodrug
distribution proﬁle before and after activation.Introduction
Advances in cancer diagnosis have led to major improvements
in the early detection of clinically-localized prostate cancers.1
Because of the adverse eﬀects of prostatectomy and external
beam radiotherapy (impotence, incontinence, etc.), in most
patients this low-to-moderate risk form of prostate cancer has
been traditionally managed through active surveillance
programs, which has resulted in an increment in the risk of
dying from prostate malignancies.2,3 Focal therapies were
introduced to facilitate localized tumour treatment with pres-
ervation of healthy prostate tissue, thus reducing the morbidity
associated with whole-gland treatments without jeopardizing
cancer control.1,3 Although current technologies mediating local
treatment of disease (e.g. brachytherapy, external-beam focal
radiotherapy, drug-eluting devices) can successfully improve
a patient's quality of life, they have important limitations4 thatitute of Genetics and Molecular Medicine,
, Edinburgh EH4 2XR, UK. E-mail: Asier.
lasgow, Bearsden, Glasgow G61 1QH, UK.
G61 1BD, UK
etics & Molecular Medicine, University of
H4 2XR, UK
n (ESI) available: Synthesis and
methods, in vivo/ex vivo protocols and
Chemistry 2018either restrict their widespread clinical use (high cost of bra-
chytherapy and external-beam focal radiotherapy) or the dura-
tion of their therapeutic eﬀect (radioisotope's short half-life and
limited drug cargo capacity of brachytherapy and controlled-
release implants, respectively).
Our capacity to visualize and modulate physiological and
pathological processes in the biological milieu has expanded
enormously in the last 15 years through the development of
a rich diversity of bioorthogonal tools and processes.5–9 Among
them, the use of abiotic transition metals (ruthenium,10–14
palladium,15–21 copper,22–24 gold25–27) has emerged to facilitate
the catalytic modication or manufacture of biomolecules and
xenobiotics in living systems, contributing to the advent of
a new prodrug modality that is not activated by a metabolic
event but through a bioorthogonal bond cleavage reaction.9
Exploration of this novel prodrug paradigm in combination
with heterogeneous Pd catalysis has stimulated the develop-
ment of masking strategies that eﬃciently suppress the bioac-
tivity of diﬀerent classes of therapeutic agents while enabling
selective drug activation – via Pd-mediated N- or O-dealkylation
– both in vitro and in vivo.20,28–31 It is proposed that, by surgical
implantation of Pd-containing inserts in a tumour followed by
systemic administration of Pd-activatable therapeutic precur-
sors, bioorthogonal drug release could take place exclusively in
the disease site and minimise adverse eﬀects in distant organs
and tissues. Since the triggering mechanism is a catalytic
process, multiple doses of one or more prodrugs could be
intratumourally activated by the same implant to extend and/orChem. Sci.
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View Article Onlinecustomize the therapeutic intervention, thereby facilitating an
adaptive form of local chemotherapy that can respond to the
severity and progression of the disease. Although studies in
mammal models supporting the eﬀectiveness of such an
approach to treat tumours locally have not yet been reported,
recent studies with Pd-based nanostructures have shown their
capacity to generate tumour-controlling levels of drugs in xeno-
gras in mice.32,33 However, the development of cancer-targeting
nanotechnologies remain a signicant challenge by itself.34
From a translational perspective, the use of activating
devices that can be surgically implanted in or near the tumour
using well-established clinical procedures3,35 would ensure that
the release of cytotoxic agents occurs exclusively at the disease
site. Essential questions such as appropriate implantation
protocols, stability and safety of the catalyst in vivo and optimal
biodistribution of the prodrug before and aer activation need
to be rst addressed to translate this novel therapeutic modality
into a medically-viable alternative to brachytherapy and drug
eluting devices. In our path towards this goal, herein we report
the development of Pd devices of optimal size for ultrasound-
guided intratumoural insertion and Pd-activatable prodrugs of
doxorubicin: a strongly uorescent cytotoxic drug that allowed
us to monitor biodistribution in prostate cancer explants.
Screening in state-of-the-art cancer models provided funda-
mental insights into the safety and catalytic properties of the
activating device, and into the prodrug activation process.Results and discussion
Design and synthesis of bioorthogonal prodrugs of
doxorubicin
Doxorubicin, 1, is an anthracycline anticancer antibiotic used
alone or in combination in the treatment of a wide range of
hematological and solid malignancies.36 Aer entering cells by
diﬀusion, this potent cytotoxic drug engages with various cyto-
plasmic and nuclear targets to synergistically disrupt cellular
function in cancer cells and induce apoptosis (Scheme 1).37 1 has
a multitude of moderate to severe side eﬀects that negativelyScheme 1 Overview of the strategy and research work. Prodrugs 2a–dw
carbonate. Pd-devices of a range of sizes (from 110 to 10 mm in diamet
conditions, in cell culture and in prostate cancer explants.
Chem. Sci.impact on its therapeutic window, limiting its maximum tolerated
dose and frequency of administration (typically administered as
a single intravenous infusion in days 1 and 2 of 21 day cycles). The
most serious adverse eﬀect of 1 is cardiotoxicity, typically observed
by an early onset of cardiomyopathy that may progress to
myocardial infarction.38 As a result, much of the research per-
taining to 1 and their anthracycline analogues focuses on sup-
pressing the cardiotoxic eﬀect of this class of cytotoxic drugs. A
variety of prodrug strategies are currently under investigation to
improve tumour targetability39–43 and have shown that blockade of
the primary amino group of the daunosamine moiety of 1
signicantly reduces the bioactivity of the resulting derivative.
Based on this evidence, the masking of the NH2 group as
a carbamate group was investigated to develop novel
biochemically-stable, Pd-sensitive prodrugs of 1 (Scheme 1).
Four carbamate derivatives of 1 were prepared as shown in
Scheme 1 (see full experimental protocols in the ESI†). As the
propargyloxycarbonyl (Poc) has been previously shown to be
relatively resistant to metabolic activation and sensitive to Pd
catalysis, derivative 2a was developed as a positive control,
whereas the Cbz-protected analogue 2b (which is expected to be
even more biochemically stable than Poc but unreactive to Pd
catalysis under physiological conditions28) was used as a nega-
tive control. With the aim of increasing steric hindrance to
further protect the carbamate bond from unspecic enzymatic
cleavage, novel compounds containing a propargyloxybenzyl
carbonyl (PBC) group were developed to enhance the metabolic
stability of the derivatives whilst providing sensitivity to Pd
catalysis. The para and ortho isomers 2c and 2d, which are
designed to undergo 1,6- or 1,4-elimination upon O-depro-
pargylation (ESI, Fig. S1†), were prepared to test which position
provides superior protection and, consequently, a greater ther-
apeutic window relative to the active drug (EC50 (2c, d)/EC50 (1)).Cytotoxicity study: drug vs. prodrug
The eﬃcacy of the deactivation strategy was evaluated by
treating human prostate cancer DU145 and glioma U87 cellsere prepared by reacting 1with their corresponding 4-nitrophenyl (LG)
er) were developed to investigate prodrug activation in biocompatible
This journal is © The Royal Society of Chemistry 2018
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View Article Online(models of human cancers that are clinically treated with local
therapies)3,35 for 5 d with increasing concentrations of 1 and 2a–
d (0.001 to 10 mM). EC50 values were calculated from the
generated 10-point semilog dose–response curves (see ESI,
Fig. S2†) and plotted in Table 1. All prodrugs showed a signi-
cant reduction in cytotoxicity relative to 1. A direct relationship
between the reduction of bioactivity and increasing steric bulk
around the carbamate group was consistently observed. Deriv-
ative 2a (containing the small Poc group) showed a relatively low
diﬀerence in activity compared to 1 (30–40 fold). Notably, PBC-
masked prodrugs 2c and 2d exhibited much greater reduction
of cytotoxicity, with the ortho analog 2d displaying a diﬀerence
in antiproliferative activity of more than two orders of magni-
tude relative to unmodied drug 1 (approx. 350- and 150-fold in
DU145 and U87, respectively). These results indicate that the
masking group of 2d provides superior protection to the
carbamate bond against unspecic biological cleavage, even
compared to the para analog 2c and without the need of further
increment of its size.Table 1 Calculated EC50 values (mM) for 1 and 2a–d treatment in
DU145 and U87 cells
Cell line DU145 U87
Reagent EC50 EC50 (2)/EC50 (1) EC50 EC50 (2)/EC50 (1)
1 0.02 — 0.08 —
2a 0.83 41.5 2.49 31
2b 2.69 134.5 3.13 39
2c 5.54 277 5.27 66
2d 7.13 356.5 11.8 147.5
Fig. 1 (A) Lateral view of 120 hpf zebraﬁsh larvae after exposition to 50 mM
E3 medium only (untreated) were used as negative controls. Cardiac ede
Additional toxicity in the eyes and the brain is also apparent. Scale bar ¼ 2
for zebraﬁsh populations in 0.1% DMSO (black), E3 medium alone (untrea
increasing concentrations). Zebraﬁsh populations treated with >50 mM o
SD from n ¼ 3 (15 ﬁsh per biological replicate); p < 0.0001, **** (ANO
This journal is © The Royal Society of Chemistry 2018Zebrash cardiotoxicity study
As mentioned above, the induction of cardiotoxicity is the most
severe side eﬀect of 1. Given the greater therapeutic window
aﬀorded by 2d, an in vivo cardiotoxicity assay was designed to
study its eﬀect on the heart of developing zebrash in
comparison to 1. Dechorionated zebrash embryos (1 dpf) were
treated for 4 days with 1 or 2d at a range of concentrations (50–
200 mM) and then imaged (brighteld and uorescent micros-
copy). Embryos in E3 medium alone or with DMSO were used as
negative controls. To determine the enlargement of the heart
(¼estimate of pericardial edema), the ratio between the cardiac
area and the total body of the treated sh was measured and
compared with the untreated controls. As shown in Fig. 1,
treatment of 1 at 50 mM induced signicant increment of the
cardiac area, with 100% lethality observed in all populations
treated at higher concentrations. In contrast, 2d did not induce
lethality or cardiac edema even up to 200 mM; well above the
theoretical blood concentration achieved with the maximum
therapeutic dosage of clinical dosing regimens.36 Since spec-
trophotometry analysis of the optical properties of 1 and 2d
showed similar red uorescent properties (ESI, Fig. S3†), drug/
prodrug distribution patterns were analyzed by uorescent
microscopy (Ex/Em ¼ 520/560 nm). Image analysis showed that
signicant levels of 1 accumulated across the body of the
zebrash, including the heart area, while 2d did not (ESI,
Fig. S4†). This observation is consistent with 2d's lack of
capacity to engage with the in vivo molecular targets of 1.Prodrug-into-drug conversion studies
Pd-devices were prepared from amino-functionalized
TentaGel® HL resins of 110 mm in average diameter (Rappof 1 or 50–200 mMof 2d for 4 d. Zebraﬁsh treatedwith 0.1%DMSO and
ma (only observed for ﬁsh treated with 1) is indicated with a red arrow.
0 mm. (B) Histogram displaying the ratio of cardiac area/total body area
ted, grey), 1 at 50 mM (red) and 2d at 50–200 mM (light to dark blue with
f 1 died during treatment and were excluded from analysis. Error bars:
VA).
Chem. Sci.
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View Article OnlinePolymere GmbH) as previously described.20 Content in Pd metal
was determined to be 4.47% w/w by inductively coupled plasma
optical emission spectrometry (ICP-OES). The conversion of
inactive 2a–d into cytotoxic 1 was rst tested by performing
a Pd-mediated activation assay in cancer cell culture at a single
concentration, using cell viability measurements as a functional
readout of the experiment. DU145 cells were treated with pro-
drugs 2a–d (0.3 mM) and Pd-devices (0.6 mg mL1) and cell
viability determined at day 5 using the PrestoBlue® reagent.
Cells treated with only Pd-devices (0.6 mg mL1) or 2a–d (0.3
mM) were used as negative controls and unmodied 1 (0.3 mM)
as positive control.
As expected, Cbz-protected 2b displayed no signs of toxicity
either on its own or in the presence of the catalyst, which
conrms its resistance to both metabolic and Pd-mediated
activation (ESI, Fig. S5†). On the contrary, prodrugs 2a–2d eli-
cited no harm on their own but signicant antiproliferative
eﬀects in the presence of the catalytic devices, thus proving the
selective in situ generation of 1 in response to the presence of
Pd. However, the assay revealed a statistically-signicant gap in
cytotoxicity between 1 and the prodrug/Pd-devices combina-
tions, particularly for prodrugs 2c and 2d. By simply mixing the
prodrugs and the Pd-devices in a test tube, it was visibly noticed
that the devices had a remarkable capacity to sequester 2d fromFig. 2 (A) Sequestration eﬀect of prodrug 2d by Pd-devices. 100 mM of
stirred for 30 min. The mixtures were then frozen by immersing the tubes
for prodrugs 2a–c. (B) ICP-OES determination of Pd loading in Pd-devic
devices (top; 450 magniﬁcation) and 30 mm Pd-devices (bottom; 80
with 30 mm and 110 mmPd-devices in DU145 (left) and U87 (right) cancer
and 2d + 0.6 mg mL1 30 mm Pd-devices (purple), and 2d + 0.6 mg mL
generated by measuring cell viability at day 5 using PrestoBlue® reagen
Chem. Sci.the solution, an eﬀect that was not seen for 1 (Fig. 2A). The
polymeric component of these devices is made of TentaGel®,
a copolymer consisting of a low crosslinked polystyrene (PS)
matrix on which polyethylene glycol (PEG) is graed.44 Based on
the strong “trapping” eﬀect observed for 2d, we reasoned that
the lipophilic polystyrene core of the devices were likely
responsible for capturing the prodrug, partially deterring its
eﬀective interaction with the catalyst and, in turn, resulting in
a moderate reduction of the reaction rate and subsequent
liberation of 1 into the cell culture.
Aiming to optimize the functionality of the devices, we
prepared, characterized and tested a range of Pd-devices using
polymer resins of reduced size and greater PEG/PS ratio
(¼increased hydrophilicity). Pd-functionalized devices with
sizes of 10, 20, 30 and 75 mm were synthesized using commer-
cially available TentaGel® resins (Rapp Polymere GmbH)
following the same protocol used for the preparation of 110 mm
Pd-devices.20 ICP-OES analysis demonstrated the presence of
the metal in each of the devices, although lower Pd content was
observed in the smaller ones (Fig. 2B). The catalytic capacity of
the devices was tested by 24 h treatment with nonuorescent
bis-N,N0-(propargyloxycarbonyl)rhodamine 110 (3) in cell
culture conditions (PBS + 10% serum, pH ¼ 7.4, 37 C). This
assay is based on the uorogenic release of rhodamine 110 (4)1 or 2d and 1 mg mL1 of 110 mm Pd-devices were mixed in PBS and
in liquid nitrogen and photographed. Equivalent results were observed
es ranging from 110 to 10 mm in diameter. SEM images of 110 mm Pd-
0 magniﬁcation). Scale bar ¼ 100 mm. (C) Study of the activation of 2d
cell culture at a range of concentrations. Experiments: 1 (red), 2d (blue),
1 110 mm Pd-devices (green). Semi-log dose–response curves were
t. Error bars: SD from n ¼ 3.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineupon Pd-mediated O-depropargylation of 3. Fluorescence
intensity was measured with a spectrophotometer. As shown in
Fig. S5C (ESI),† the 30 mm Pd-devices displayed slightly superior
catalytic activity then the rest of the devices. The catalytic
properties of the devices remained stable aer storage at 4 C
for 20 months (ESI, Fig. S6†). Study of the tolerability of DU145
and U87 cells to the presence of 30 mm Pd-devices showed full
biocompatibility at the concentrations tested (ESI, Fig. S7†).
Prodrug candidate 2d was then incubated with 30 mm Pd-
devices in serum-free media at physiological conditions (pH ¼
7.4, isotonicity, 37 C) and analyzed by UPLC. Remarkably,
whereas the analysis indicated that the 30 mm devices also
sequestered the prodrug very rapidly (note the immediate
disappearance of the prodrug signal from the chromatogram in
Fig. S8 of the ESI†), it showed eﬃcient synthesis and release of
1, an optimal situation for the therapeutic goal of the strategy.
In principle, the superior aﬃnity of the prodrug for the devices
could potentially serve to pull the prodrug molecules out of
circulation, whereby they would be uncaged and released as an
active drug at the intended site of treatment. As shown in
Fig. 2C, dose–response studies in cancer cell culture using 30
mm Pd-devices provided equivalent curves and EC50 values for
the prodrug 2d/Pd combinations and the unmodied drug 1 in
both cell lines (see complete studies in ESI, Fig. S9 and S10†).
Based on the safety, catalytic performance and convenient size
of the 30 mm Pd-devices, they were then chosen for the next
phase of the investigation.In vivo/ex vivo assays: implantation, safety and stability of Pd-
devices
Given the medical interest of our team in developing improved
prostate cancer treatments, a state-of-the-art orthotopic murine
model of human prostate cancer45,46 was used to test the in vivo
biocompatibility and functional stability of the Pd-devices.
DU145 prostate cancer cells were carefully inserted in the
prostate of anesthetized male mice (n¼ 4) and tumours allowed
to grow for 4 weeks (see full details in the ESI†). One of the
clinical logistics of implant-based focal therapy modalities is to
insert the devices in the tumour with high precision. In bra-
chytherapy, this procedure is facilitated by the echogenic nature
of the radioactive inserts (which are made of metal), as itFig. 3 (A) Schematic of the in vivo intratumoural insertion of 30 mm P
Ultrasound image captions of the prostate tumour area of an anaesthetis
10 s (right).
This journal is © The Royal Society of Chemistry 2018enables to control the correct placement of the radioactive
pellets using ultrasound imaging.47 Since the Pd-devices
contain a signicant amount of metallic material, we envi-
sioned that ultrasound-guided insertion would be an optimal
method to place such small devices with millimeter range
precision in the prostate tumour (Fig. 3A). A standard 1 mL
syringe tted with a 9-gauge needle was used to deliver the
devices. The size of the 30 mm Pd-devices was found optimal to
perform this procedure with ease, whereas partial blockage of
the needle was observed with the larger devices. Hence, 1 mg of
30 mm Pd-devices suspended in 25 mL of sterile PBS was injected
into the prostate tumour of anaesthetized mice under real time
monitoring with ultrasound imaging. Fig. 3B and Movie S1†
shows the highly echogenic Pd-devices being precisely inserted
into a hypoechogenic area of the tumour. The mice were then
transferred for recovery. The injected region was imaged 30 min
aer the procedure (Movie S2†) and monitored for 3 days (ESI,
Fig. S11†) to ensure that Pd-devices did not leak out the tumour.
Tumour growth was not aﬀected by the presence of the devices.
Apart from the presence of the tumour, animals remained
healthy and behaved normally during the time of the study.
Aer 21 days, the animals were sacriced. Necropsy of animals
and gross observation of major organs showed no macroscopic
signs of toxicity. Tumours were removed and sliced in half to
study the distribution of the Pd-devices (ESI, Fig. S11†). Exam-
ination of the tissue surrounding the injection site further
conrmed that the devices had not been displaced from the
cancerous tissue.
The catalytic capacity of Pd-devices hosted in the prostate
tumour of live mice for 3 weeks (21 day-in-tumour Pd-devices)
was then tested ex vivo. Explants bearing Pd-devices were
sliced longitudinally using a rat brain slicer instrument into
1 mm sections, soaked in media containing uorogenic probe 3
and visualized by live-cell imaging confocal microscopy for 24 h
(using the green uorescent channel with 488 nm laser excita-
tion). The catalytic activity of 21 day-in-tumor Pd-devices was
compared with devices directly implanted in the explants (0 day-
in-tumour Pd-devices). Incubation of Pd-free explants with 3, 4
or DMSO were used as controls. As shown in Fig. 4A, a rapid
increase in uorescent intensity (¼release of uorescent dye 4)
was achieved by treating Pd-bearing explants with 3. Impor-
tantly, equivalent uorescence generation was observed withd-devices (1 mg in 25 mL of PBS) into a murine prostate tumour. (B)
ed mouse taken during the implantation procedure at t ¼ 0 s (left) and
Chem. Sci.
Fig. 4 (A) Live-cell imaging study of the catalytic activity of tumour-implanted Pd-devices: 0 d vs. 21 d after implantation. Pd-bearing explants (n
¼ 2) were incubated with 3 (100 mM) and imaged by live-cell confocal microscopy (488 laser excitation) at 3, 9 and 24 h. The presence of the Pd-
devices is indicated with white arrows. Note that Pd-devices are identiﬁed due to their capacity to quench green ﬂuorescence.27 Images of the
controls (3 alone (100 mM); 4 alone (100 mM); and DMSO) are shown at 24 h. Pictures were generated using ImageJ software. Scale bar ¼ 30 mm.
(B) Live-cell imaging study of the Pd-mediated conversion of inactive 2d into cytotoxic 1 in a human prostate tumour explant model. Images of
a representative tumour explant (n ¼ 2) bearing 21 day-in-tumor Pd-devices after treatment with 2d (100 mM) in the presence of DAPI for 24, 36
and 48 h (left panel). Tissue samples were imaged under laser excitation at 405 nm (for DAPI staining, in blue) and 543 nm (for 2d/1 distribution, in
red). The presence of the Pd-devices, indicated with white arrows, is identiﬁed by a bright ﬂuorescence signal in the red channel (as previously
reported,48 red ﬂuorescence is not quenched by Pd). Images of the Pd-free controls 1 (100 mM,mid panel) and 2d (100 mM, right panel) are shown
at 48 h. Pictures were generated using ImageJ software. Scale bar ¼ 30 mm.
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View Article Onlineboth 0- and 21 day-in-tumour Pd-devices, evidence that main-
taining the devices in living tissue for extended periods of time
does not have a negative impact in the underlying turnover rate
of the devices. In contrast, in the absence of the activation
devices, tumour explants treated with 3 showed minimal
background signal (Fig. 4A, right). The good biocompatibility
and catalytic stability of the catalyst in living tissue, which are
herein shown for the rst time for a bioorthogonal catalyst that
has been hosted for weeks in a tumour in vivo, are optimal
features that support the use of heterogeneous Pd devices for
site-specic prodrug activation in precision medicine.Chem. Sci.Ex vivo prodrug-into-drug conversion study
Next, the capacity of the devices to generate therapeutic
(¼cytotoxic) levels of 1 from an inactive dose of 2d was tested in
tumour explants bearing 21 day-in-tumour Pd-devices. Tissue
samples were treated for 48 h in media containing 100 mM of 2d
in the presence of DAPI (a nuclei stain not permeable in viable
cells). Treatment of Pd-free explants (in the presence of DAPI)
with either 2d (100 mM) or 1 (100 mM) were used as a negative
and positive control, respectively. Cancer cell viability and
prodrug/drug distribution was monitored by live-cell imagingThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineconfocal microscopy using two laser excitations: 405 nm to
image nuclei staining by DAPI (¼dying/dead cells) and 543 nm
to visualize 2d and/or 1 (the spectroscopic properties of both
compounds are indistinguishable; see Fig. S3†). In the absence
of Pd-devices (Fig. 4B, right panel), 48 h treatment with 2d did
not elicit any sign of cell death in the cancer tissue. Analysis of
the red uorescent channel shows that 2d was not retained
inside the cancer cells, which is consistent with its expected
inability to bind with the intracellular targets of doxorubicin. A
drastically diﬀerent distribution prole was observed upon
treatment with 1, with bright red uorescence being accumu-
lated in the cells (Fig. 4B, middle panel; and ESI, Fig. S12†).
Remarkably, the distribution pattern of the red uorescence
signal from explants bearing Pd-devices and treated with 2d
became identical to that of the explants directly treated with 1
aer 48 h, indicating that 2d has been chemically converted into
1. It is also noteworthy that compound 2d rapidly entered the
devices during the rst hours of treatment, making the Pd-
devices patently visible under the 543 nm laser excitation
(Fig. 4B, see panels at 24 and 36 h). This observation agrees with
the high capacity of the devices to “pull” the prodrug from the
environment (Fig. 2A). Importantly, the 2d/Pd-devices treatment
combination induced a strong cytotoxic eﬀect (DAPI staining),
equivalent to that of 1 treatment, demonstrating the in situ
bioorthogonal generation of bioactive levels of drug. Ex vivo
studies with the 0 day-in-tumour Pd-devices provided equiva-
lent results (ESI, Fig. S12†).
Last, samples of an explant containing 21 day-in-tumour Pd-
devices and previously treated with uorogenic compound 3
were washed and subsequently incubated with either 1, prodrug
2d or DMSO for 48 h. Tissue samples were then xed and
analysed by immunohistochemical staining with caspase 3
(apoptosis biomarker) or g-H2AX (biomarker for DNA double-
strand breaks) antibodies (ESI, Fig. S13†). As expected,
damaged cells (indicated by brown staining) were only observed
in the Pd-containing samples treated with 1 and 2d. This test
agrees with the inert nature of the devices and supports their
capacity to activate multiple doses of prodrug.
Conclusions
In conclusion, fundamental insights into the validity, reliability
and clinical feasibility of a novel approach to accurately target
chemotherapy spatially within a tumour have been reported.
This therapeutic approach, which is conceived for the treatment
of localised cancers, consists of two components: (i) an inactive
derivative of a cytotoxic drug designed to be specically acti-
vated by palladium chemistry; and (ii) an inert implantable
polymer-based device functionalised with Pd nanoparticles to
catalyse drug conversion and release in a spatially controlled
manner. As part of the investigation, a novel caged doxorubicin
was developed by blocking the NH2 group of the drug's sugar
moiety with a Pd-labile PBC group. The derivative having the
propargyloxy moiety in ortho was found to oﬀer superior
reduction of bioactivity than the one in para and high sensitivity
to Pd catalysis. Studies in zebrash proved that the cardiotoxic
eﬀect induced by doxorubicin was abolished in the cagedThis journal is © The Royal Society of Chemistry 2018precursor; a clinically-relevant result that to the best of our
knowledge is shown in this animal model for the rst time for
a doxorubicin prodrug. Pd-devices of optimised size and activity
were also developed and tested in a state-of-the-art orthotopic
murine model of human prostate cancer. The devices showed
high echogenicity, enabling precise injection into the tumour
using ultrasound scanning, an image-guided microsurgical
technique widely used in the clinic. The study provided
evidence of the non-perturbing eﬀect of the devices to the mice
and of the resilience and biocompatibility of the catalyst to the
tumour microenvironment. Devices hosted in a tumour of mice
for 21 d elicited catalytic release of a uorogenic probe and
a caged doxorubicin at an equivalent rate than freshly injected
devices. Ex vivo time-lapse imaging enabled to monitor the
distinct distribution proles of the drug and the inactive
precursor, and the capacity of the devices to “sequester” circu-
lating prodrug molecules and generate cytotoxic levels of drug
in the tumour explant. This investigation provides compelling
evidence that heterogeneous palladium catalysts can be applied
as bioorthogonal tools to enable local treatment of disease and
reports a standardized preclinical methodology to perform and
study local bioorthogonal release of bioactive substances in
preclinical disease models.Conﬂicts of interest
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